Gulnara Yuldasheva | Drug Synergy | Women Researcher Award

Published on by Global Diseases Research

Women Researcher Award

Research Profile
Affiliation Scientific Center for Anti-Infective Drug
Country Kazakhstan
Scopus ID 21735405800
Documents 7
Citations 35
h-index 5
Subject Area Drug synergy
Event Global Diseases Research Awards
ORCID 0000-0003-2881-0307

Gulnara Yuldasheva is associated with the Scientific Center for Anti-Infective Drug in Kazakhstan and has contributed to the advancement of research in drug synergy and anti-infective therapeutic studies. Her scholarly work reflects a focused engagement in antimicrobial research, pharmaceutical sciences, and collaborative approaches to disease-related investigations. The academic profile demonstrates measurable research visibility through indexed publications, citations, and international scholarly recognition.[1]

Abstract

The Women Researcher Award recognizes academic and scientific contributions that demonstrate relevance, scholarly consistency, and engagement with emerging challenges in biomedical and pharmaceutical sciences. Gulnara Yuldasheva has contributed to the field of anti-infective drug research with particular attention to drug synergy, antimicrobial investigations, and interdisciplinary pharmaceutical approaches. Her research activities are represented through indexed scientific publications and citation-based academic visibility, indicating active participation in internationally recognized scientific communication.[1][2]

Keywords

  • Drug synergy
  • Anti-infective research
  • Pharmaceutical sciences
  • Biomedical research
  • Women in science
  • Global Diseases Research Awards

Introduction

Research in anti-infective therapeutics continues to play a significant role in addressing global public health challenges related to infectious diseases and antimicrobial resistance. Scientific investigations involving drug synergy provide insights into the combined effects of therapeutic compounds and contribute to the optimization of treatment strategies. Researchers engaged in this domain support evidence-based approaches that may improve clinical outcomes and pharmaceutical innovation.[2]

Gulnara Yuldasheva’s academic profile reflects participation in research initiatives connected with anti-infective drug development and interdisciplinary pharmaceutical studies. Her scholarly contributions demonstrate engagement with research dissemination through indexed databases and internationally accessible scientific literature. Such contributions align with the broader objectives of scientific collaboration and innovation in health-related research environments.[1]

Research Profile

The research profile of Gulnara Yuldasheva is associated with studies in anti-infective pharmacology and drug synergy analysis. Her work has contributed to the understanding of therapeutic interactions and scientific approaches relevant to infectious disease management. Indexed publications and citation metrics indicate continuing scholarly engagement within biomedical and pharmaceutical research communities.[1]

  • Affiliated with the Scientific Center for Anti-Infective Drug.
  • Research specialization includes drug synergy and anti-infective therapeutics.
  • Indexed scientific publications available through Scopus.
  • Recognized through measurable citation impact and academic visibility.
  • Engaged in interdisciplinary biomedical and pharmaceutical studies.

Research Contributions

Research contributions associated with Gulnara Yuldasheva include scientific investigations into anti-infective compounds, synergistic drug interactions, and pharmaceutical research methodologies. Such studies support broader scientific understanding related to therapeutic combinations and their relevance in infectious disease management.[2]

Drug synergy research is important for evaluating combined therapeutic effectiveness, minimizing resistance development, and identifying optimized treatment approaches. Through scholarly publication activity, Yuldasheva has contributed to ongoing scientific discussions in this specialized area of pharmaceutical sciences and biomedical investigation.[3]

Publications

The publication record associated with Gulnara Yuldasheva reflects contributions to scientific literature indexed within internationally recognized academic databases. Her scholarly output demonstrates participation in peer-reviewed communication relevant to anti-infective pharmacology and biomedical research.[1]

  1. Research studies addressing anti-infective therapeutic strategies and drug interaction analysis.
  2. Molecular Modeling of the Anti-HIV Activity Mechanism of Iodine-Containing Drugs Armenicum and FS-1Article link copied! [3]
  3. Iodine-Based Coordination Compounds: A Strategy Toward Antibiotic Potentiation [4]

Research Impact

Research impact may be evaluated through publication indexing, citation activity, and scholarly engagement across scientific platforms. The citation profile associated with Gulnara Yuldasheva demonstrates recognition within academic literature and indicates that her work has contributed to discussions related to pharmaceutical and anti-infective sciences.[1]

The documented h-index and citation metrics reflect measurable academic visibility within the scientific community. Such indicators support the significance of continued research participation and contribution to interdisciplinary biomedical knowledge dissemination.[1]

Award Suitability

The Women Researcher Award within the Global Diseases Research Awards framework recognizes scientific contributions that support research excellence, innovation, and scholarly engagement in health sciences. Gulnara Yuldasheva’s profile demonstrates alignment with these objectives through her involvement in anti-infective drug research, indexed scientific output, and measurable citation impact.[5]

Her academic activities indicate sustained participation in biomedical and pharmaceutical investigations relevant to global health and therapeutic innovation. The combination of publication visibility, research specialization, and international indexing supports the suitability of recognition within a research-oriented academic award context.[1]

Conclusion

Gulnara Yuldasheva has contributed to scientific research associated with anti-infective therapeutics and drug synergy studies through indexed publications and interdisciplinary academic engagement. Her scholarly profile reflects measurable research visibility and participation in pharmaceutical science communication. The academic contributions and citation-based impact presented within this profile demonstrate relevance to contemporary biomedical research and support recognition within the Women Researcher Award category of the Global Diseases Research Awards.[1][5]

References

  1. Elsevier. (n.d.). Scopus author details: Gulnara Yuldasheva, Author ID 21735405800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=21735405800
  2. World Health Organization. (2023). Antimicrobial resistance and anti-infective therapeutic research.
    https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
  3. Yuldasheva, G. A., Argirova, R., & Ilin, A. I. (2023). Molecular modeling of the anti-HIV activity mechanism of iodine-containing drugs Armenicum and FS-1. ACS Omega, 8(9), 8617–8624
    https://doi.org/10.1021/acsomega.2c07720

  4. Shepilov, D., Askarova, D., Seisembekova, A., Turganbay, S., Jumagaziyeva, A., Bukeyeva, T., Yuldasheva, G., Temir, N., Ivanova, L. N., Zubenko, N., & Kenesheva, S. (2026). Iodine-based coordination compounds: A strategy toward antibiotic potentiation. International Journal of Molecular Sciences, 27(10), 4292.
    https://doi.org/10.3390/ijms27104292

  5. Global Diseases Research Awards. (n.d.). Women Researcher Award recognition and event information.
    https://globaldiseases.org/

Peter Asaga Mac | Infectious diseases | Best Researcher Award

Published on by Global Diseases Research

Dr. Peter Asaga Mac | Infectious diseases | Best Researcher Award 

Senior clinical research fellow | University Hospital Freiburg | Germany

Dr. Peter Asaga Mac is a dedicated researcher at Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany, specializing in infectious and zoonotic diseases. His scientific work focuses on understanding the epidemiology, immune response, and transmission dynamics of emerging viral infections, particularly mosquito-borne diseases such as Chikungunya and Dengue. Through a combination of field-based studies, serological analyses, and molecular surveillance, Dr. Mac investigates how co-circulating arboviruses interact within populations and contribute to public health challenges in endemic regions, especially in Africa. His notable publication, “An Undetected Expansion, Spread, and Burden of Chikungunya and Dengue Cocirculating Antibodies in Nigeria” (Zoonotic Diseases, 2024), provides valuable insight into the unnoticed expansion of these viruses and their long-term implications for disease control strategies. Dr. Mac’s research is characterized by its translational value—bridging scientific discovery with actionable health interventions to improve epidemic preparedness and response. His collaborations with international scientists strengthen global efforts to monitor zoonotic threats and develop more resilient surveillance systems. Despite being an early-career researcher, his contributions are gaining recognition within the academic community. With 3 publications, 14 citations  and an h-index of 2, Dr. Mac’s growing academic footprint reflects his potential to make lasting contributions to infectious disease research, particularly in the areas of viral immunology, epidemiological modeling, and global health resilience. His commitment to evidence-based solutions continues to shape a better understanding of emerging diseases and their impact on human health worldwide.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

1. Chackalackal, D. J., Al-Aghbari, A. A. A., Jang, S. Y., Ramirez, T. R., Vincent, J., Joshi, A., et al. (2021). The Covid-19 pandemic in low- and middle-income countries: Who carries the burden? Review of mass media and publications from six countries. Pathogens and Global Health, 115(3), 178–187.
Cited by: 49

2. Mac, P. A., Suleiman, A. C., & Airiohuodion, P. E. (2019). High prevalence of hepatitis B virus infection among pregnant women attending antenatal care in Central Nigeria. Journal of Infectious Diseases and Epidemiology, 5(1), 068.
Cited by: 34

3. Mac, P. A., Asheadzi, H. F., Gideon, A., Thaker, P., & Airiohuodion, P. (2019). Prevalence of Plasmodium falciparum among Nigerians in Abuja and Central States: A comparative analysis of sensitivity and specificity using rapid diagnostic test and microscopy. International Journal of Tropical Diseases, 1, 014.
Cited by: 22

4. Mac, P. A., Kroeger, A., & Airiohuodion, P. E. (2019). Needs assessment of emergency medical and rescue services in Abuja/Nigeria and environs. BMC Emergency Medicine, 19(78), 8.
Cited by: 21

5. Mac, P. A., Airiohuodion, P. E., Yako, A. B., et al. (2022). The seroprevalence and hidden burden of chikungunya endemicity and malaria mono- and coinfection in Nigeria. International Journal of Environmental Research and Public Health, 19(15), 8896.
Cited by: 19